05/01/2024
4:08 PM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
04/30/2024
7:53 PM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G | |
04/22/2024
3:15 PM | Adage Capital Management, L.P. (Reporting)
Atchinson Robert (Reporting)
EyePoint Pharmaceuticals (Issuer)
Gross Phillip (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
04/02/2024
4:27 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/08/2024
12:53 PM | EyePoint Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/07/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/04/2024
4:37 PM | EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
|
03/04/2024
4:40 PM | EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
6:01 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2024
8:08 PM | EyePoint Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
02/13/2024
4:37 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:38 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:38 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:39 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:40 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
11:00 AM | EyePoint Pharmaceuticals (Subject)
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
02/07/2024
6:54 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/06/2024
9:55 AM | EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SC 13G/A | |
02/05/2024
4:15 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
3:22 PM | EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/30/2024
3:53 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
4:51 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
4:54 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:24 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:26 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2024
3:50 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2024
3:25 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024
3:42 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024
3:19 PM | EyePoint Pharmaceuticals (Subject)
Paggiarino Dario A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/22/2024
3:19 PM | EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/16/2024
5:55 PM | EyePoint Pharmaceuticals (Issuer)
Ocumension Therapeutics (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/16/2024
5:01 PM | EyePoint Pharmaceuticals (Issuer)
Liu Ye (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/11/2024
4:33 PM | EyePoint Pharmaceuticals (Subject)
Ocumension Therapeutics (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2024
3:53 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/10/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/09/2024
8:28 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:17 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:53 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:53 PM | ANDO GORAN (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:54 PM | DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:54 PM | Duty Stuart (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
The AI Stock that’s Disrupting Every Industry (Ad) Move over Nvidia. There’s a new hot AI play that has soared 960% in the past year.
One high-flying artificial intelligence stock has soared 960% over the past year and may soon become as familiar as Nvidia… Here's the Ticker >>> |
01/09/2024
7:55 PM | EyePoint Pharmaceuticals (Issuer)
Landis John B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:56 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:04 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:07 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:09 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:11 PM | EyePoint Pharmaceuticals (Issuer)
Pine Michael Craig (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:12 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2024
5:37 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4/A | |
01/02/2024
4:41 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/15/2023
4:14 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2023
3:52 PM | Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/08/2023
4:28 PM | EW Healthcare Partners, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13D/A | |
12/07/2023
8:21 PM | EyePoint Pharmaceuticals (Issuer)
Ocumension Therapeutics (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/07/2023
8:03 PM | EyePoint Pharmaceuticals (Issuer)
Liu Ye (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/07/2023
5:11 AM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
12/06/2023
4:18 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
4:19 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
4:20 PM | EyePoint Pharmaceuticals (Issuer)
Pine Michael Craig (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
3:39 PM | Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/05/2023
7:54 AM | EyePoint Pharmaceuticals (Subject)
Ocumension Therapeutics (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/04/2023
4:31 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
12/04/2023
3:34 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144/A | |
12/04/2023
3:15 PM | EyePoint Pharmaceuticals (Subject)
Pine Michael Craig (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/04/2023
3:16 PM | EyePoint Pharmaceuticals (Subject)
Paggiarino Dario A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/04/2023
2:39 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/04/2023
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/09/2023
7:00 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/03/2023
2:47 PM | EyePoint Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/01/2023
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/30/2023
11:15 PM | EyePoint Pharmaceuticals (Filer)
| Form EFFECT | |
10/20/2023
4:15 PM | EyePoint Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
10/20/2023
4:18 PM | EyePoint Pharmaceuticals (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
10/17/2023
3:47 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2023
3:48 PM | Duty Stuart (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/17/2023
3:49 PM | Duty Stuart (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/16/2023
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/13/2023
6:06 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/11/2023
10:15 AM | EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SC 13G/A | |
09/11/2023
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/06/2023
6:10 PM | Essex Woodlands Fund IX-GP, L.P. (Reporting)
Essex Woodlands IX, LLC (Reporting)
EW Healthcare Partners, L.P. (Reporting)
EW Healthcare Partners-A, L.P. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4/A | |
09/01/2023
3:51 PM | Essex Woodlands Fund IX-GP, L.P. (Reporting)
Essex Woodlands IX, LLC (Reporting)
EW Healthcare Partners, L.P. (Reporting)
EW Healthcare Partners-A, L.P. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2023
4:46 PM | Essex Woodlands Fund IX-GP, L.P. (Reporting)
Essex Woodlands IX, LLC (Reporting)
EW Healthcare Partners, L.P. (Reporting)
EW Healthcare Partners-A, L.P. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2023
4:22 PM | EW Healthcare Partners, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13D/A | |
08/30/2023
4:32 PM | Essex Woodlands Fund IX-GP, L.P. (Reporting)
Essex Woodlands IX, LLC (Reporting)
EW Healthcare Partners, L.P. (Reporting)
EW Healthcare Partners-A, L.P. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4/A | |
08/28/2023
5:32 PM | Essex Woodlands Fund IX-GP, L.P. (Reporting)
Essex Woodlands IX, LLC (Reporting)
EW Healthcare Partners, L.P. (Reporting)
EW Healthcare Partners-A, L.P. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/24/2023
4:30 PM | Essex Woodlands Fund IX-GP, L.P. (Reporting)
Essex Woodlands IX, LLC (Reporting)
EW Healthcare Partners, L.P. (Reporting)
EW Healthcare Partners-A, L.P. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/22/2023
3:23 PM | EW Healthcare Partners-A, L.P. (Reporting)
EyePoint Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/22/2023
3:17 PM | EW Healthcare Partners, L.P. (Reporting)
EyePoint Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/04/2023
2:09 PM | EyePoint Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/02/2023
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
The AI Stock that’s Disrupting Every Industry (Ad) Move over Nvidia. There’s a new hot AI play that has soared 960% in the past year.
One high-flying artificial intelligence stock has soared 960% over the past year and may soon become as familiar as Nvidia… Here's the Ticker >>> |
07/12/2023
5:51 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2023
5:52 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2023
5:53 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2023
6:06 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/10/2023
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/26/2023
4:10 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/22/2023
8:15 AM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/22/2023
8:15 AM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/22/2023
8:16 AM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
